Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 38%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Glaukos Corp has demonstrated strong financial performance, with glaucoma revenue reaching $110 million in Q3 2025, surpassing consensus estimates of $101 million and reflecting a 45% growth compared to the previous quarter. The company's domestic glaucoma revenue also exceeded expectations at $81 million, achieving a 57% increase, while overall international glaucoma revenue grew 17% year-over-year. Furthermore, Glaukos has revised its revenue expectations for the iDose product to approximately $136.8 million for FY25, indicating positive momentum and increasing investor confidence in its innovative product lineup.

Bears say

Glaukos Corp faces a negative financial outlook primarily due to anticipated lower growth in the minimally invasive glaucoma surgery (MIGS) market, along with a slower-than-expected uptake of its iDose and infinite surgical devices. The company's legacy surgical glaucoma revenue has already declined by 4.7% to $40.8 million, and projections indicate a potential material decline in Corneal Health revenues tied to the transition of Epioxa. Additionally, external factors such as changes in the reimbursement landscape and increased competition from new market entrants further exacerbate the company's financial challenges.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.